- Home
- NRIX vs UP Comparison
NRIX vs UP Comparison
Compare NRIX & UP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- UP
- Stock Information
- Founded
- NRIX 2009
- UP 2013
- Country
- NRIX United States
- UP United States
- Employees
- NRIX N/A
- UP N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- UP Aerospace
- Sector
- NRIX Health Care
- UP Consumer Discretionary
- Exchange
- NRIX Nasdaq
- UP Nasdaq
- Market Cap
- NRIX 1.4B
- UP 1.2B
- IPO Year
- NRIX 2020
- UP N/A
- Fundamental
- Price
- NRIX $19.60
- UP $1.67
- Analyst Decision
- NRIX Strong Buy
- UP
- Analyst Count
- NRIX 17
- UP 0
- Target Price
- NRIX $30.29
- UP N/A
- AVG Volume (30 Days)
- NRIX 771.6K
- UP 1.1M
- Earning Date
- NRIX 02-13-2025
- UP 03-06-2025
- Dividend Yield
- NRIX N/A
- UP N/A
- EPS Growth
- NRIX N/A
- UP N/A
- EPS
- NRIX N/A
- UP N/A
- Revenue
- NRIX $56,424,000.00
- UP $833,669,000.00
- Revenue This Year
- NRIX N/A
- UP $38.03
- Revenue Next Year
- NRIX $3.79
- UP $25.66
- P/E Ratio
- NRIX N/A
- UP N/A
- Revenue Growth
- NRIX N/A
- UP N/A
- 52 Week Low
- NRIX $7.65
- UP $1.52
- 52 Week High
- NRIX $29.56
- UP $4.59
- Technical
- Relative Strength Index (RSI)
- NRIX 48.04
- UP 42.70
- Support Level
- NRIX $18.75
- UP $1.58
- Resistance Level
- NRIX $20.50
- UP $1.71
- Average True Range (ATR)
- NRIX 1.08
- UP 0.10
- MACD
- NRIX 0.18
- UP 0.01
- Stochastic Oscillator
- NRIX 70.00
- UP 41.43
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.